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Abstract 
Objective: 
To determine whether acetyl-L-carnitine (ALC), a metabolite necessary for energy metabolism and 
essential fatty acid anabolism, might help attention-deficit/hyperactivity disorder (ADHD). Trials in Down’s 
syndrome, migraine, and Alzheimer’s disease showed benefit for attention. A preliminary trial in ADHD 
using L-carnitine reported significant benefit. 
Method: 
A multi-site 16-week pilot study randomized 112 children (83 boys, 29 girls) age 5-12 with 
systematically diagnosed ADHD to placebo or ALC in weight-based doses from 500 to 1500 mg b.i.d. The 
2001 revisions of the Conners’ parent and teacher scales (including DSM-IV ADHD symptoms) were 
administered at baseline, 8, 12, and 16 weeks. Analyses were ANOVA of change from baseline to 16 weeks 
with treatment, center, and treatment-by-center interaction as independent variables. 
Results: 
The primary intent-to-treat analysis, of 9 DSM-IV teacher-rated inattentive symptoms, was not 
significant. However, secondary analyses were interesting. There was significant (p = 0.02) moderation by 
subtype: superiority of ALC over placebo in the inattentive type, with an opposite tendency in combined 
type. There was also a geographic effect (p = 0.047). Side effects were negligible; electrocardiograms, lab 
work, and physical exam unremarkable. 
Conclusion: 
ALC appears safe, but with no effect on the overall ADHD population (especially combined type). 
It deserves further exploration for possible benefit specifically in the inattentive type. 
Introduction 
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most common childhood mental 
health problem and often persists into adulthood. It is characterized by inattentiveness, 
distractibility, disorganization, overactivity, and impulsiveness. Although several 
well-documented treatments are available (FDA-approved medications and behavioral treatment), 
the search continues for additional treatment options, especially for those who do not respond to 
established treatment, who have severe side effects, or who have personal preference to avoid 
schedule II or IV medication. L-carnitine is one of many alternatives considered on theoretical 
grounds. 
L-carnitine is a natural mammalian metabolite necessary for fatty-acid metabolism and 
energy production (Brass, 1992). It acts as a carrier in the transport of long chain fatty acids across 
the inner mitochondrial membrane for β-oxidation in all tissues; in skeletal and cardiac muscle, 
β-oxidation supplies the major fuel (Brass 1992; Bremer 1983). L-carnitine not only binds fatty 
acids for their mitochondrial oxidation, but also plays a role in removing potentially toxic 
metabolic intermediates, such as carboxylic acids (Brass 1992,1994; Chalmers et al. 1983; De 
Sousa et al. 1986; Roe et al. 1984). Carnitine is present in high concentrations in all tissues as 
either free carnitine or as acylcar-nitines, which include acetyl-L-carnitine (ALC), its most 
abundant short chain ester (Goa and Brogden 1987). 
Omnivorous humans synthesize only 25% of daily carnitine requirement themselves, the 
other 75% coming from the diet (daily requirements are approximately 200 mg) (Rebouche and 
Seim 1998). Acetyl-L-carnitine is synthesized from l-carnitine by the enzyme carnitine 
acyl-transferase (CAT), located on the matrix side of the inner mitochondrial membrane (Bremer 
1983). CAT is also able to catalyze the reverse reaction, releasing acetate, a key metabolite in the 
trafficking between neurons and glia (Sonnewald et al. 1993). 
The effect of ALC on brain metabolism and function has been studied in several 
experimental models. Energy metabolism of the brain has been studied with spectroscopy (31P and 
1H nuclear magnetic resonance) in animal models, which has shown that ALC can stimulate 
lipid-mediated energy production in the central nervous system (CNS) (Gorini et al. 1998; 
Kuratsune et al. 1997; Maccari et al. 1990; Sonnewald et al. 1993). In addition, the role of acetate 
moieties released from CAT in lipid metabolism has been studied using radioactive ALC, showing 
that the acetyl moiety of ALC was incorporated into saturated (60%), monounsaturated (15%), and 
polyunsaturated (25%) fatty acids. Injection in the ventricle of radioactive glucose, the major 
source of acetyl-CoA in the CNS, revealed that glucose was a precursor of saturated (85%) and 
monounsaturated (15%) but not of polyunsaturated fatty acids (Ricciolini et al. 1998). 
ALC is suspected of having an impact on several neurotransmitter pathways, particularly 
cholinergic and downstream dopaminergic. The drug affects mitochondrial respiration by 
increasing cytochrome oxidase activity and reducing glutamate dehydrogenase activity in rat 
mitochondria, indicating a possible effect on neurotransmitter metabolism at a synaptic level 
(Gorini et al. 1999). The cholinergic effects have been tested in rat brain synaptosomal 
preparations, which confirmed that ALC could provide the acetyl moiety that transfers to choline, 
generating acetylcholine, thereby acting as a precursor of this neurotransmitter (Dolezal and Tucek 
1998). In addition, ALC also exerts mild M3 muscarinic receptor agonism in rats, simulating 
acetylcholine release (Imperato et al. 1989). The compound significantly increases glutamatergic 
receptor binding, and protects against age-related reductions in the GABA/benzodiazepine 
receptor binding capacity (White and Scates 1990). 
Previous clinical studies indicate that some physical symptoms in ADHD are similar to 
symptoms observed in essential fatty deficiency (Burgess et al. 2000; Colquhoun and Bounday 
1981; Stevens et al. 1995). Arduini et al. (1992, 1994) reported that carnitine is required to 
incorporate arachidonic acid (AA, 20:4n-6) and docosahexaenoic acid (DHA, 22:6n-6), into red 
blood cell membranes. In an established rat model that produces hyperactivity and learning deficit 
following neonatal anoxia, ALC has improved learning and reduced hyperactivity (Dell’Anna et al 
1997). In a small double blind, placebo-controlled trial, ALC (50 mg/kg b.i.d.) significantly 
reduced hyperactivity in school-aged boys diagnosed with the fragile X syndrome (Torrioli et al. 
1999). De Falco (1994) reported benefit on memory and attention in an open study in patients with 
Down’s syndrome. In a placebo-controlled trial in pediatric migraine, Nicolodi and Sicuteri (2000) 
also reported significantly improved attention and memory with ALC 25 mg/kg. Van Oudheusden 
reported that L-Car-nitine 100 mg/kg/day exerted a significant beneficial effect on inattention in 
children with ADHD in a crossover study (Van Oudheusden and Scholte 2002). Thus there are 
both animal and human data suggesting a role for l-carnitine and its moieties in brain function, 
fatty acid metabolism, neurotransmission, and attention. 
Therefore we undertook a multi-site, placebo-controlled pilot study in well-diagnosed 
children with ADHD, using pharmaceutical-grade ALC. 
Method 
In a multi-site parallel-group double-blind randomized pilot trial, children age 5-12 with 
DSM-IV ADHD diagnosed by Diagnostic Interview Schedule for Children (Shaffer et al. 1996) 
and by clinical evaluation by a licensed physician or psychologist were randomly assigned to 
either placebo or acetyl-l-carnitine for 16 weeks, with parent-and teacher-rated scales at baseline, 8 
weeks, 12 weeks, and 16 weeks. Written permission from parents and assent from children were 
obtained using informed consent documents and procedures approved by the local institutional 
review boards before any study assessments or treatment. 
Inclusion criteria 
Inclusion criteria were: boys and girls age 5–12 with investigator-diagnosed ADHD (any 
of the 3 subtypes) confirmed by the Diagnostic Interview Schedule for Children (DISC-IV); an 
item mean on either the 18 DSM-IV ADHD symptoms or nine inattentive symptoms of 1.5 or 
more (on a 0 to 3 scale) averaging both informants (parent and teacher); reasonably good health 
during the four weeks immediately prior to initial screening as demonstrated by medical history, 
physical examination, and laboratory testing; failure of FDA-approved therapy or stopped therapy 
due to adverse events or declined or stopped approved therapy because of parental/guardian 
concern about the risks of approved drugs. (Categorical diagnosis followed DSM-IV criteria based 
on clinical interview of parent and child, assisted by the DISC-IV. In addition, a dimensional 
criterion of 1.5 item mean rating of ADHD symptoms (either nine inattentive or all 18) was taken 
from the DSM-IV items embedded in the Conners’ (2001) revised long version parent and teacher 
scales.) 
Exclusion criteria 
Exclusion criteria were: severe medical, surgical, or neurological problems; anything that 
would interfere with treatment or assessment; co-morbid diagnoses requiring treatment with 
psychoactive medication; a prior history of carnitine therapy in the past three months prior to 
baseline; use of any investigational drug in the 30 days prior to baseline; use of any medication or 
supplement to treat ADHD; a frank deficiency of magnesium or zinc, increased levels of lead 
above 10mcg/dL; impaired renal or liver function; pathologically abnormal peripheral blood 
count; neuroleptic medication in the past six months; body weight below 13.5 kg, missing 
one-quarter of school days in the previous two months; another child in the same household or 
classroom already in the study; no telephone; a non-English speaking primary caretaker; important 
changes expected in school or home situation, (divorce, relocating) during the course of the trial 
period; or actively suicidal or homicidal. 
Treatment 
Participants were treated with either pharmaceutical-grade ALC or identical-appearing and 
tasting placebo as a soluble strawberry-flavored powder in doses ranging from 500 mg to 1500 mg 
b.i.d. depending on the weight of child: 13.5-30 kg = 0.5 g b.i.d.; >30-50 kg = 1.0 g b.i.d.; and >50 
kg = 1.5 g b.i.d. If a subject crossed a weight threshold during the trial, the dose was increased to 
the new weight class; this happened only once. 
Measure 
Behavior and attention were assessed by Conners’ revised long version parent and teacher 
scales (Conners, 2001) at baseline, 8 weeks, 12 weeks, and 16 weeks. The primary outcome 
measure was the mean of the 9 DSM-IV inattention symptoms embedded in the Conners’ Teacher 
Rating Scale—Revised (CTRS-R), which rates symptoms and problems from 0 (not at all) to 3 
(very much or very often). This was selected as primary because preliminary data from 
Alzheimer’s disease, migraine, and Down’s syndrome research and a previous small pilot study in 
ADHD had suggested more effect on attention than on hyperactivity-impulsivity, and teacher 
observations were considered the best naturalistic measure of attention. Secondary measures 
included all 18 DSM-IV symptoms by teacher and parent, the Conners’ Scale totals by parent and 
teacher as global measures, and Clinical Global Impressions (CGI) (Guy 1976) by clinician at 
baseline, 8, 12, and 16 weeks. The CGI has two scales: Severity (CGI-S) and improvement 
(CGI-I), both scored 1-7, with lower number better. A CGI-S of 1 is normal, 2 borderline, 3 mild, 
and 4 moderate. A CGI-I of 1 (very much improved) or 2 (much improved) was considered a 
favorable response to be considered a “responder.” Safety measures included vital signs and 
recording of adverse events at 8, 12, and 16 weeks, and blood counts/chemistries, urinalysis, and 
electrocardiograms (ECGs) at baseline and 16 weeks. 
Data analysis 
Treatment balance for age, sex, race, and subtype of ADHD was tested, and the baseline 
scores of the primary and secondary outcome measures were tested for treatment-group bias. 
Continuous variables were tested with a one-way analysis of variance (ANOVA). Categorical 
variables were tested with a general chi-square test (or Fisher’s exact test if any expected cell count 
was < 5). The primary intention-to-treat (ITT) analysis on the change from baseline to week 16 in 
teacher-rated 9 inattentive symptoms was an ANOVA model that considered the treatment, the 
center, and the treatment-by-center interaction as the independent variables. Alpha was set at 0.05 
for the single primary outcome test. The same analysis was repeated for the secondary outcomes of 
change in parent and teacher-rated 18 DSM-IV ADHD symptoms and total Conners’ sums, with 
alpha set at 0.05 because of the exploratory nature of the additional tests. CGI scores were 
summarized descriptively without statistical test: a score of 1 or 2 on the CGI-I counted as a 
response, and at the other end of the scale, scores of 5-7 were counted as worse. Exploratory 
moderator analyses for sex, age, ADHD subtype, and weight were performed by adding them to 
the intention to treat (ITT) analysis of the primary outcome and deriving the interaction term. 
Similarly, a mediator analysis of dose was performed. Safety variables were compared by 
treatment group. 
Results 
One hundred eighteen children were randomized (60 placebo and 58 ALC) and started 
treatment; 112 had at least one post-baseline assessment available for intent-to-treat analysis; 92 
completed 8-week assessment, and 81 completed the whole study. Of 58 children randomized to 
ALC, 42 completed, for an attrition rate of 28%. For placebo, 39 out of 60 completed, for an 
attrition rate of 35%. The treatment-group difference was accounted for by attrition of combined 
type, greater in placebo (13/33, 39%) than in ALC (9/38, 24%) Attrition of inattentive type for 
placebo (7/25) was comparable to that of ALC (6/18). By study end, the placebo group was almost 
evenly balanced between inattentive and combined type (18 and 20, respectively) while the ALC 
group had more than twice as many combined (29) as inattentive (11) type. Sample characteristics 
of ITT population (n = 112) are shown in Table 1. 
Outcome data are shown in Table 2. There was no significant difference on the main ITT 
outcome, teacher-rated inattention. ITT analyses of secondary measures also failed to find a 
significant difference. However, exploratory moderator analyses showed a couple of provocative 
findings. 
 Count (%) or Mean ± SD 
 Placebo ALC 
 (n = 59) (n = 53) 
Age, years 8.3 ± 2.2 8.4 ± 2.3 
Male 42 (71%) 41 (77%) 
Caucasian 41 (70%) 36 (68%) 
ADHD, Inattentive Type 25 (42%) 15 (28%) 
Combined Type 32 (54%) 35 (66%) 
Hyperactive/Impulsive Type 2 (3%) 3 (6%) 
Oppositional-defiant disorder 7 (12%) 5 (9%) 
Other comorbidity 8 (14%) 11 (21%) 
Previous ADHD medication 23 (39%) 16 (30%) 
Daily RDI multivitamins 9 (15%) 2 (4%) 
CGI-Severity (1-7 scale; 1 = normal, 4 = moderate, 5 = marked) 4.4 4.6 
Retention to end of DB of the 118 randomized 39/60 (65%) 42/58 (72%) 
Weight-based dose assignment   
0.5 g b.i.d. 30 (50%) 28 (48.3%) 
1.0 g b.i.d. 23 (38%) 23 (39.7%) 
1.5 g b.i.d. 7 (11.7%) 7 (12.1%) 
*ITT = those with at least one post-treatment assessment; N = 112; DB = double blind. 
Table 1. Sample Characteristics of Intention-to-Treat Sample (ITT)* 
The primary outcome measure (ADHD inattentive symptoms) showed a significant (p = 
0.02) moderating effect of diagnostic subtype in the ITT sample due to the inattentive type of 
ADHD showing superiority of ALC over placebo, in contrast to the combined type showing a 
tendency the opposite direction. The interaction (Fig. 1) was significant (p = 0.02) even 
   n = 112  
  Placebo ALC  
  (n = 59) (n = 53)  
  Mean ± SD Mean ± SD p 
9-Item Inattention symptom rating by Baseline 2.23 ± 0.54 2.15 ± 0.59 0.447 
teacher End (wk 16) 1.91 ± 0.72 1.93 ± 0.74  
18-Item ADHD symptom rating by Baseline 1.87 ± 0.58 1.85 ± 0.61 0.235 
teacher End 1.62 ± 0.71 1.72 ± 0.74  
9-Item Inattention symptom rating by Baseline 2.26 ± 0.47 2.45 ± 0.47 0.289 
parent End 1.94 ± 0.71 2.02 ± 0.73  
18-Item ADHD symptom rating by Baseline 2.04 ± 0.47 2.22 ± 0.49 0.318 
parent End 1.77 ± 0.66 1.84 ± 0.68  
Full Conners’-Revised rating by Baseline 1.40 ± 0.45 1.40 ± 0.52 0.448 
teacher End 1.25 ± 0.57 1.31 ± 0.58  
Full Conners’-Revised rating by Baseline 1.45 ± 0.39 1.58 ± 0.39 0.291 
parent End 1.25 ± 0.45 1.28 ± 0.49  
CGI-I Week 8 4 (7%) 7 (13%) N.S. 
N(%) 1 or 2 (responder) End (wk 16) 8 (14%) 9 (17%)  
CGI-I Week 8 2 (3%) 1 (2%) N.S. 
N(%) 5–7 (worse) End (wk 16) 7 (12%) 2 (4%)  
*Primary outcome measure regardless of subtype. 
As planned from study inception, the 9 hyperactive-impulsive symptoms were not separately analyzed, but 
were included in the 18 DSM-IV-TR symptoms. 
CGI-I = Clinical Global Impressions-Improvement. 
Table 2. ADHD symptom outcome, rated by teachers and parents on conners’ rating scales—revised 
(Intention-to-Treat Population). All Scores Except CGI-I are Item Means on 0–3 Metric 
F
th
A
th
after con
T
100-150 
(n = 68) o
0.047) du
showing 
having a 
analysis. 
T
significan
unremark
F
ig. 1. Interactio
e intention-to-
DHD symptom
e whole trial. L
trolling for s
here was als
miles northw
n the ITT p
e to the thre
a tendency t
higher prop
Moderator/m
here were n
tly differen
able. 
ig. 2. Site distr
n of attention
treat (ITT) Pop
s on Conners
ower score is
ex, which is
o an interest
est of the A
rimary outc
e NW-of-A
he opposite 
ortion of ina
ediator ana
o safety prob
t between tre
ibution. Three
-deficit/hypera
ulation. P=0.0
’ Teacher Ratin
 better. 
 well known
ing geograp
llegheny M
ome, the int
lleghenies s
direction. T
ttentive type
lyses by sex
lems (Table
atment grou
 sites with soli
ctivity disorde
2 after contro
g Scale-Revis
 to be confo
hic effect (F
ountains (n =
eraction of s
ites showing
his effect co
 (41% vs. 3
, age, weigh
 3). Vital si
ps, and elec
d circles are 10
r (ADHD) Sub
lling for sex. C
ed (CTRS-R)
unded with
ig. 2): When
 44) were c
ite and treat
 superiority
uld not be e
1%) because
t, and dose
gns and adv
trocardiogra
0-150 miles n
type with Tre
TRS = item m
, the primary o
 subtype. 
 the three si
ompared to 
ment was si
 of ALC and
xplained by
 subtype wa
 were not sig
erse events 
ms and phy
orthwest of A
 
atment Condit
ean of 9 inatte
utcome variab
tes located a
all the other
gnificant (p
 the other s
 those three
s covaried i
nificant. 
were not 
sical exams 
 
llegheny Moun
ion in 
ntive 
le for 
bout 
 sites 
 = 
ites 
 sites 
n the 
were 
tains; 
